34.60
price up icon0.12%   0.04
after-market After Hours: 34.60
loading
Tg Therapeutics Inc stock is traded at $34.60, with a volume of 1.11M. It is up +0.12% in the last 24 hours and up +23.75% over the past month. TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, it has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. Its pipeline includes UBLITUXIMAB, SUB-Q UBLITUXIMAB, and AZER-CEL. Geographically, it generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from the international market.
See More
Previous Close:
$34.56
Open:
$34.76
24h Volume:
1.11M
Relative Volume:
0.55
Market Cap:
$5.53B
Revenue:
$616.29M
Net Income/Loss:
$447.18M
P/E Ratio:
12.46
EPS:
2.7771
Net Cash Flow:
$-24.99M
1W Performance:
+1.14%
1M Performance:
+23.75%
6M Performance:
-1.28%
1Y Performance:
-11.35%
1-Day Range:
Value
$33.99
$34.85
1-Week Range:
Value
$33.41
$34.93
52-Week Range:
Value
$25.28
$46.48

Tg Therapeutics Inc Stock (TGTX) Company Profile

Name
Name
Tg Therapeutics Inc
Name
Phone
(212) 554-4484
Name
Address
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY
Name
Employee
399
Name
Twitter
@TGTherapeutics
Name
Next Earnings Date
2025-03-03
Name
Latest SEC Filings
Name
TGTX's Discussions on Twitter

Compare TGTX vs VRTX, REGN, ARGX, ALNY, ONC

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
TGTX icon
TGTX
Tg Therapeutics Inc
34.60 5.52B 616.29M 447.18M -24.99M 2.7771
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
441.70 113.01B 12.07B 3.95B 3.19B 15.33
REGN icon
REGN
Regeneron Pharmaceuticals Inc
753.93 79.87B 14.34B 4.50B 3.77B 41.56
ARGX icon
ARGX
Argen X Se Adr
840.87 51.51B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
333.39 45.29B 3.71B 313.75M 465.38M 2.2571
ONC icon
ONC
Beone Medicines Ltd Adr
319.94 34.41B 5.36B 287.73M 924.18M 2.5229

Tg Therapeutics Inc Stock (TGTX) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-06-25 Resumed H.C. Wainwright Buy
Jul-10-25 Resumed Goldman Neutral
Oct-29-24 Initiated TD Cowen Buy
Aug-02-23 Upgrade Goldman Sell → Neutral
Jun-26-23 Resumed Jefferies Buy
May-20-22 Initiated BofA Securities Underperform
Feb-23-22 Reiterated B. Riley Securities Buy
Nov-15-21 Downgrade Goldman Neutral → Sell
Apr-20-21 Initiated Goldman Neutral
Apr-19-21 Reiterated H.C. Wainwright Buy
Sep-01-20 Initiated JP Morgan Overweight
Aug-11-20 Reiterated H.C. Wainwright Buy
Jun-05-20 Initiated Evercore ISI Outperform
Jan-17-20 Reiterated H.C. Wainwright Buy
Nov-27-19 Resumed B. Riley FBR Buy
Feb-06-19 Resumed Jefferies Buy
Sep-25-18 Downgrade Raymond James Strong Buy → Outperform
Mar-09-18 Reiterated B. Riley FBR, Inc. Buy
Dec-01-17 Resumed B. Riley FBR, Inc. Buy
Nov-14-17 Resumed H.C. Wainwright Buy
Apr-25-17 Initiated Jefferies Buy
Mar-06-17 Reiterated FBR & Co. Outperform
Oct-06-16 Resumed Brean Capital Buy
May-27-16 Initiated SunTrust Buy
Dec-01-15 Initiated FBR Capital Outperform
Sep-09-15 Initiated Raymond James Strong Buy
Aug-12-15 Resumed H.C. Wainwright Buy
Jun-19-15 Reiterated Brean Capital Buy
Dec-11-14 Reiterated ROTH Capital Buy
Dec-10-14 Reiterated ROTH Capital Buy
View All

Tg Therapeutics Inc Stock (TGTX) Latest News

pulisher
09:10 AM

TGTX Advances with Phase 3 Trial Completion for Briumvi Treatment - GuruFocus

09:10 AM
pulisher
07:51 AM

TG Therapeutics completes enrollment in subcutaneous BRIUMVI trial By Investing.com - Investing.com India

07:51 AM
pulisher
07:30 AM

MS trial completion moves TG closer to at-home BRIUMVI option - Stock Titan

07:30 AM
pulisher
Apr 13, 2026

Update Report: Should you avoid TG Therapeutics Inc stock right now2026 Fed Impact & Weekly Return Optimization Plans - baoquankhu1.vn

Apr 13, 2026
pulisher
Apr 12, 2026

Price-Driven Insight from (TGTX) for Rule-Based Strategy - Stock Traders Daily

Apr 12, 2026
pulisher
Apr 12, 2026

TG Therapeutics Inc at JPMorgan Healthcare Conference Transcript - GuruFocus

Apr 12, 2026
pulisher
Apr 10, 2026

TG Therapeutics (TGTX) reports financial results for Q4 and full year 2025 - MSN

Apr 10, 2026
pulisher
Apr 09, 2026

Fed Watch: Does TG Therapeutics Inc stock benefit from AI growth2026 Trade Ideas & Weekly Consistent Profit Watchlists - baoquankhu1.vn

Apr 09, 2026
pulisher
Apr 09, 2026

Gains Recap: Is TG Therapeutics Inc a turnaround storyQuarterly Market Summary & Safe Capital Investment Plans - baoquankhu1.vn

Apr 09, 2026
pulisher
Apr 08, 2026

TG Therapeutics, Inc. (TGTX) Stock Forecasts - Yahoo! Finance Canada

Apr 08, 2026
pulisher
Apr 08, 2026

BofA Securities Maintains TG Therapeutics(TGTX.US) With Sell Rating, Maintains Target Price $15 - Moomoo

Apr 08, 2026
pulisher
Apr 07, 2026

Fed Meeting: Can TG Therapeutics Inc expand into new marketsMarket Trend Report & Daily Momentum Trading Reports - baoquankhu1.vn

Apr 07, 2026
pulisher
Apr 07, 2026

Gains Recap: Is TG Therapeutics Inc undervalued by DCF analysis - baoquankhu1.vn

Apr 07, 2026
pulisher
Apr 05, 2026

TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

Apr 05, 2026
pulisher
Apr 04, 2026

TGTX PE Ratio & Valuation, Is TGTX Overvalued - Intellectia AI

Apr 04, 2026
pulisher
Apr 04, 2026

TG Therapeutics Inc (NASDAQ:TGTX): An Affordable Growth Stock with Strong Momentum - ChartMill

Apr 04, 2026
pulisher
Apr 04, 2026

TG Therapeutics, Inc. (TGTX) Stock forecasts - Yahoo Finance UK

Apr 04, 2026
pulisher
Apr 03, 2026

TG THERAPEUTICS INC (1TGTX.MI) Balance Sheet - Yahoo! Finance Canada

Apr 03, 2026
pulisher
Apr 03, 2026

TG Therapeutics, Inc. (TGTX) Stock Price, News, Quote & History - Yahoo! Finance Canada

Apr 03, 2026
pulisher
Apr 02, 2026

TG Therapeutics Inc. (TGTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Apr 02, 2026
pulisher
Apr 02, 2026

TGTX Stock Price, Quote & Chart | TG THERAPEUTICS INC (NASDAQ:TGTX) - ChartMill

Apr 02, 2026
pulisher
Apr 01, 2026

(TGTX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily

Apr 01, 2026
pulisher
Mar 31, 2026

TG Therapeutics: Briumvi Performance Aiding Upside, Buybacks Limiting Downside (TGTX) - Seeking Alpha

Mar 31, 2026
pulisher
Mar 31, 2026

Analyst Calls: Is TG Therapeutics Inc undervalued by DCF analysis2026 Reactions & Long-Term Safe Investment Plans - baoquankhu1.vn

Mar 31, 2026
pulisher
Mar 30, 2026

TG Therapeutics, Inc. $TGTX Shares Bought by JPMorgan Chase & Co. - MarketBeat

Mar 30, 2026
pulisher
Mar 29, 2026

TG Therapeutics stock price forecast: overbought readings persist as TGTX consolidates below SMA-200 - Traders Union

Mar 29, 2026
pulisher
Mar 29, 2026

Nordea Investment Management AB Buys Shares of 79,696 TG Therapeutics, Inc. $TGTX - MarketBeat

Mar 29, 2026
pulisher
Mar 29, 2026

TG Therapeutics, Inc. $TGTX Shares Purchased by Assenagon Asset Management S.A. - MarketBeat

Mar 29, 2026
pulisher
Mar 27, 2026

Vanguard disaggregates holdings after realignment — TG Therapeutics (TGTX) - Stock Titan

Mar 27, 2026
pulisher
Mar 26, 2026

TG Therapeutics announces $100M share buyback program - MSN

Mar 26, 2026
pulisher
Mar 25, 2026

US$750 Million Credit Facility Could Be A Game Changer For TG Therapeutics (TGTX) - simplywall.st

Mar 25, 2026
pulisher
Mar 24, 2026

A Look At TG Therapeutics (TGTX) Valuation After New US$750 Million Credit Facility - Yahoo Finance

Mar 24, 2026
pulisher
Mar 24, 2026

1,922,410 Shares in TG Therapeutics, Inc. $TGTX Acquired by Congress Asset Management Co. - marketbeat.com

Mar 24, 2026
pulisher
Mar 22, 2026

Day Trade: Is TG Therapeutics Inc still a buy after recent gains2026 Review & Stepwise Trade Execution Plans - baoquankhu1.vn

Mar 22, 2026
pulisher
Mar 22, 2026

CapEx per share of TG Therapeutics, Inc. – MIL:1TGTX - TradingView

Mar 22, 2026
pulisher
Mar 22, 2026

TG Therapeutics Credit Deal And Valuation Gap Catch Investor Attention - simplywall.st

Mar 22, 2026
pulisher
Mar 21, 2026

TG Therapeutics Files Procedural 8-K on Financial Obligation - The Globe and Mail

Mar 21, 2026
pulisher
Mar 21, 2026

(TGTX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily

Mar 21, 2026
pulisher
Mar 21, 2026

TG Therapeutics, Inc. (TGTX) Enters $750 Million Term Loan Agreement – SEC 8-K Filing Summary - Minichart

Mar 21, 2026
pulisher
Mar 20, 2026

Form 8K TG Therapeutics Inc For: 20 March By Investing.com - Investing.com Canada

Mar 20, 2026
pulisher
Mar 20, 2026

Form 8K TG Therapeutics Inc For: 20 March - Investing.com

Mar 20, 2026
pulisher
Mar 20, 2026

TG Therapeutics, Inc. Enters into First Amendment Agreement for $750 Million Term Loan Facility and $250 Million Uncommitted Additional Facility - marketscreener.com

Mar 20, 2026
pulisher
Mar 20, 2026

TG Therapeutics (TGTX) secures $750M 2026 Term Loan maturing 2031 - Stock Titan

Mar 20, 2026
pulisher
Mar 20, 2026

TG Therapeutics, Inc. (NASDAQ:TGTX) Q4 2025 earnings call transcript - MSN

Mar 20, 2026
pulisher
Mar 20, 2026

TG Therapeutics (TGTX) Secures $750 Million Credit Facility - GuruFocus

Mar 20, 2026
pulisher
Mar 20, 2026

TG Therapeutics secures $750M credit facility with Blue Owl By Investing.com - Investing.com India

Mar 20, 2026
pulisher
Mar 19, 2026

TG Therapeutics board expands share repurchase program to $300M - TipRanks

Mar 19, 2026
pulisher
Mar 19, 2026

TG Therapeutics secures $750M credit facility with Blue Owl - investing.com

Mar 19, 2026
pulisher
Mar 19, 2026

TG Therapeutics (TGTX) Secures $750M Credit Facility, Expands Sh - GuruFocus

Mar 19, 2026
pulisher
Mar 19, 2026

TG Therapeutics Receives $500 Million in New Capital From Blue Owl, Increases Share Buyback - marketscreener.com

Mar 19, 2026
pulisher
Mar 19, 2026

TG Therapeutics secures an additional $500 million in non-dilutive capital from Blue Owl and expands share repurchase program to $300 million - marketscreener.com

Mar 19, 2026

Tg Therapeutics Inc Stock (TGTX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$54.26
price up icon 2.69%
$48.70
price down icon 0.25%
$99.47
price up icon 1.08%
$152.54
price up icon 3.76%
$146.74
price down icon 4.34%
ONC ONC
$319.94
price up icon 3.21%
Cap:     |  Volume (24h):